作者
Sapan Bhuta, Waleed Khokher, Nithin Kesireddy, Saffa Iftikhar, Azizullah Beran, Mohammed Mhanna, Neha J Patel, Mitra Patel, Cameron Burmeister, Ragheb Assaly
发表日期
2022/5/1
来源
American journal of therapeutics
卷号
29
期号
3
页码范围
e298-e304
出版商
LWW
简介
Background:
Recent clinical trials have investigated the use of fluvoxamine in preventing clinical deterioration in nonhospitalized patients with acute COVID-19 infection via stimulation of sigma-1 receptors, which regulates cytokine production and functional inhibition of acid sphingomyelinase activity, which may prevent infection of epithelial cells with SARS-CoV-2. However, the role of fluvoxamine is currently unclear because of a paucity of studies, particularly because the drug is being repurposed as an immunomodulatory and antiviral agent.
Study Question:
Aim of our meta-analysis was to investigate the efficacy of fluvoxamine in nonhospitalized patients with acute COVID-19 infection.
Data Source:
Comprehensive literature search of PubMed, Embase, Cochrane Library databases, and Web of Science was performed from inception to February 10, 2022, for studies comparing fluvoxamine versus placebo for …
学术搜索中的文章
S Bhuta, W Khokher, N Kesireddy, S Iftikhar, A Beran… - American journal of therapeutics, 2022